1. Home
  2. POAI vs EVAX Comparison

POAI vs EVAX Comparison

Compare POAI & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POAI
  • EVAX
  • Stock Information
  • Founded
  • POAI 2002
  • EVAX 2008
  • Country
  • POAI United States
  • EVAX Denmark
  • Employees
  • POAI N/A
  • EVAX N/A
  • Industry
  • POAI Industrial Specialties
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • POAI Health Care
  • EVAX Health Care
  • Exchange
  • POAI Nasdaq
  • EVAX Nasdaq
  • Market Cap
  • POAI 9.7M
  • EVAX 8.7M
  • IPO Year
  • POAI N/A
  • EVAX 2021
  • Fundamental
  • Price
  • POAI $1.62
  • EVAX $2.49
  • Analyst Decision
  • POAI Hold
  • EVAX Strong Buy
  • Analyst Count
  • POAI 1
  • EVAX 3
  • Target Price
  • POAI N/A
  • EVAX $33.33
  • AVG Volume (30 Days)
  • POAI 2.7M
  • EVAX 6.9M
  • Earning Date
  • POAI 03-27-2025
  • EVAX 03-26-2025
  • Dividend Yield
  • POAI N/A
  • EVAX N/A
  • EPS Growth
  • POAI N/A
  • EVAX N/A
  • EPS
  • POAI N/A
  • EVAX N/A
  • Revenue
  • POAI $1,484,223.00
  • EVAX $3,295,000.00
  • Revenue This Year
  • POAI N/A
  • EVAX $9,039.73
  • Revenue Next Year
  • POAI $569.48
  • EVAX $1.47
  • P/E Ratio
  • POAI N/A
  • EVAX N/A
  • Revenue Growth
  • POAI N/A
  • EVAX N/A
  • 52 Week Low
  • POAI $0.55
  • EVAX $2.22
  • 52 Week High
  • POAI $3.76
  • EVAX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • POAI 62.46
  • EVAX 39.85
  • Support Level
  • POAI $1.37
  • EVAX $2.30
  • Resistance Level
  • POAI $1.58
  • EVAX $2.80
  • Average True Range (ATR)
  • POAI 0.13
  • EVAX 0.51
  • MACD
  • POAI -0.01
  • EVAX 0.03
  • Stochastic Oscillator
  • POAI 93.55
  • EVAX 6.97

About POAI Predictive Oncology Inc.

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Share on Social Networks: